444 related articles for article (PubMed ID: 21393407)
1. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.
Hygino da Cruz LC; Rodriguez I; Domingues RC; Gasparetto EL; Sorensen AG
AJNR Am J Neuroradiol; 2011 Dec; 32(11):1978-85. PubMed ID: 21393407
[TBL] [Abstract][Full Text] [Related]
2. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
3. Pros and cons of current brain tumor imaging.
Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
[TBL] [Abstract][Full Text] [Related]
4. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression and pseudoresponse in the treatment of gliomas.
Brandsma D; van den Bent MJ
Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
[TBL] [Abstract][Full Text] [Related]
6. Neuroradiological response criteria for high-grade gliomas.
Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
[TBL] [Abstract][Full Text] [Related]
7. Neuroimaging and genetic influence in treating brain neoplasms.
Hygino da Cruz LC; Kimura M
Neuroimaging Clin N Am; 2015 Feb; 25(1):121-40. PubMed ID: 25476517
[TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H
Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114
[TBL] [Abstract][Full Text] [Related]
9. [Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Payer F
Wien Med Wochenschr; 2011 Jan; 161(1-2):13-9. PubMed ID: 21312094
[TBL] [Abstract][Full Text] [Related]
10. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.
Zikou A; Sioka C; Alexiou GA; Fotopoulos A; Voulgaris S; Argyropoulou MI
Contrast Media Mol Imaging; 2018; 2018():6828396. PubMed ID: 30627060
[TBL] [Abstract][Full Text] [Related]
11. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
12. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy.
Yang I; Huh NG; Smith ZA; Han SJ; Parsa AT
Neurosurg Clin N Am; 2010 Jan; 21(1):181-6. PubMed ID: 19944976
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.
Fatterpekar GM; Galheigo D; Narayana A; Johnson G; Knopp E
AJR Am J Roentgenol; 2012 Jan; 198(1):19-26. PubMed ID: 22194475
[TBL] [Abstract][Full Text] [Related]
14. Response assessment challenges in clinical trials of gliomas.
Wen PY; Norden AD; Drappatz J; Quant E
Curr Oncol Rep; 2010 Jan; 12(1):68-75. PubMed ID: 20425610
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial end points for high-grade glioma: the evolving landscape.
Reardon DA; Galanis E; DeGroot JF; Cloughesy TF; Wefel JS; Lamborn KR; Lassman AB; Gilbert MR; Sampson JH; Wick W; Chamberlain MC; Macdonald DR; Mehta MP; Vogelbaum MA; Chang SM; Van den Bent MJ; Wen PY
Neuro Oncol; 2011 Mar; 13(3):353-61. PubMed ID: 21310734
[TBL] [Abstract][Full Text] [Related]
16. Imaging of the Posttherapeutic Brain.
Telles BA; D'Amore F; Lerner A; Law M; Shiroishi MS
Top Magn Reson Imaging; 2015 Jun; 24(3):147-54. PubMed ID: 26049818
[TBL] [Abstract][Full Text] [Related]
17. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
18. Pseudoprogression in high-grade glioma.
Knudsen-Baas KM; Moen G; Fluge Ø; Storstein A
Acta Neurol Scand Suppl; 2013; (196):31-7. PubMed ID: 23190289
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice.
Boxerman JL; Shiroishi MS; Ellingson BM; Pope WB
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):649-670. PubMed ID: 27742108
[TBL] [Abstract][Full Text] [Related]
20. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
